By Manas Mishra and Manojna Maddipatla
The U.S. patent office will review patents on Alexion Pharmaceuticals Incs blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.
Found this useful? Share it with your team.
